Jeffery Marc Steinberg, M.D.
jsteinberg@smgumc.com

Board certified neurologist with a special interest in Botox therapy, sleep disorders, pain management, EEG and Electrophysiology EMG testing, headaches, Alzheimer’s disease and memory loss.

PROFESSIONAL and TEACHING ACTIVITIES

[2000–present] Practice of Neurology, Sunrise Medical Group, Hollywood, FL

[1998-present] Associate Professor, Nova University School of Medicine

[present] Medical Director, Sunrise Sleep Diagnostics, Hollywood, FL

[2000-present] Sunrise Clinical Research, Broward County, FL

MEDICAL DEGREE

[1986] St. Georges University School Of Medicine, St. George, Grenada

CERTIFICATIONS, QUALIFICATIONS AND APPOINTMENTS

[1981] Emory University, Atlanta, GA Bachelor of Arts

American Board of Psychiatry and Neurology

GRADUATE TRAINING

Residency: Neurology

[1989-1991] Kaiser Permanente Hospital, Los Angeles, CA

Internship: Neurology

 [1988-1989] University of California Davis, Sacramento, CA

Internship: Internal Medicine

[1986-1987] (St. John’s Episcopal Hospital, Queens, NY)

[1986-1987] (Hartford Hospital, Hartford, CT)

Fellowship: Sleep

[1991-1992] (Neuroelectrophysiology EMG/EEG)

AFFILIATED ASSOCIATIONS

American Academy of Neurology

American Academy of Pain Management

American Academy of Sleep Medicine

Southern Pain Society

RESEARCH, PRESENTATIONS, PUBLISHED BOOKS AND PAPERS

[1991] Rosenfeld, David, Steinberg Jeff, Jactato Capitus-Nocturna and Sleep apnea: A Case Report’ Sleep

[1991] Lebers Hereditary Opti Atrophy: Clinic and Genetic Update. American College of Surgeons San Diego, CA

[1990] Sleep Apnea and other Causes Of Daytime Somnolence. Kaiser Regional Hospital Southern Regional Meeting, Los Angeles, CA

[1997] Acute Stroke, Sponsor: Baker Norton Drug: Cervene

[1999] Acute Stroke (Phase Ila), Inpatient study, Sponsor: GlaxoWellcome, Drug: GLY, Gain America

[1999] Stroke Prevention (phase Ill), Sponsor: SmithKline Beecham, Drug:Lotrifiban 00, Bravo 030

[1999] Acute Stroke: (Phase lla), Inpatient study, GlaxoWell, Come Gain Americas

[1999] Stroke Prevention: (Phase Ill), Smithkline Beecham Lotrifiban)) BRAVO 030

[1999] HIV Neuropathy (phase IV), Sponsor: GlaxoWellcome, Drug: Lamictal trial, Lam 40006

[2000] Hyponatremia, Sponsor: Parke Davis, Drug: Conavaptan, 1025-007

[2000] Seizure Management (phase IV), Sponsor: Pharma, Drug: Keppra Keeper

[2001] Acute Stroke (phase Ila), Inpatient study, Sponsor Yamanouchi, Drug: Neuroprotective agent

[2000] Parkinson’s Psychosis (phase II), Sponsor: Bristol Meyers

[2001] Hypercholesterolemia, Sponsor: AstraZeneca, Drug:        Rosuvastatin, AZ 4522lL/0065

[2002] Hypercholesterolemia (phase IlIb), Sponsor: AstraZeneca, Drug: Atorvastatin and Simvastatin with Rosuvastatin

[2002] Migrainous Disorder (phase II), Sponsor: GlaxoSmithkline, Drug: Sumatriptan, Sum40299

[2002] Vascular Dementia (phase III), Sponsor: Eisai, Drug; Donepezil Hydrochloride

[2003] Insomnia (phase III), Sponsor: Takeda, Drug: TAK 375

 “A Double-Blind Randomized Multicenter, Parallel Group Study to Establish Dose-Response, Safety And Efficacy Zonegran ® (Zonisamide) as Monotherapy in patients with Newly Diagnosed Epilepsy”

“A 6-week, Open Label, Dose-comparison Study to Evaluate the Safety and Efficacy of Rosuvastatin Versus Altorvastatin, Pravastatin, and Simvastatin In Subjects With Hypercholesterolemia”

“An Open-label, Randomized, Multi-center, Phase IlIb, Parallel Group Switching Study to Compare the Efficacy and Safety of Lipid Lowering Agents Atorvatatin and Simvastatin with Rosuvastatin I High Risk Subjects with Type Ila and lb Hypercholesterolemia”

“A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and tolerability of oral sumatriptan 25mg, 50mg, and 100mg tablets for a single moderate or severe headache in adults diagnosed with Migrainous disorder (HIS 1.7)”

“A Multicenter, double-blind, randomized study to evaluate the safety and efficacy of lamotrigine 200mg/day, 300mg/day and 400mg/day compared with placebo in subjects with painful diabetic neuropathy”

“An Open-Label Study to Evaluate the Safety of Lamotrigine in Subjects with Painful Diabetic Neuropathy”

 “A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of XXXXXX (200 mg/day, 400 mg/day, 600                                 mg/day) as Adjunctive Therapy in Subjects with Partial Seizures with or without Secondary Generalization”

“An Open-label Extension Trial to Determine Tolerability and Efficacy of Long-Term Oral XXXXXX as Adjunctive Therapy in Patients with Partial Seizures”

Safety Evaluation of D-TRANS® fentanyl with naltrexone HCI in Opioid Tolerant Patients

“A Phase Ill, Randomized, Double-Blind, Placebo-Controlled, Outpatient, safety and Efficacy Study of XXXXXX in Adult Subjects with Chronic Insomnia”

“A Phase Ill, Randomized, Double-Blind, Placebo-Controlled, Outpatient, safety and Efficacy Study of XXXXXX in Elderly Subjects with Chronic Insomnia”

“A Phase II Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled, Multicenter, Safety and Efficacy Evaluation of Three Doses of XXX) O(X in Patients with Mild to Moderate Dementia of the Alzheimer’s Type”

“A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of XX X)(XX in Early Parkinson’s Disease Patients (study for Proof of Concept in Early Parkinson’s Disease of a Triple Reuptake Inhibitor, XX XXXX / SCEPTRE)”

“A Randomized, Double-Blind, Placebo ­Controlled, Parallel-Group, Single-Attack Study to Evaluate the Onset of Efficacy of a New Formulation of Sumatriptan Tablets 50mg and 100mg in the Acute Treatment of Migraine”

“A dose-ranging, placebo-controlled study of XX)(X>X)(XX-XX at the dose of 0.5 mg, 2 mg and 8 mg for 12 weeks in patients with mild-to-moderate Alzheimer’s Disease”

“A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of XX-XXX 25 mg in Slowing the Progression of Alzheimer’s Disease”

“A ONE YEAR, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EVALUATION OF THE EFFICACY AND SAFETY OF DONEPEZIL HYDROCHLORIDE (XXXXX) IN SUBJECTS WITH MILD COGNITIVE IMPAIRMENT”

“A two year Phase IlIb randomized, multicenter, double-blind, Sinement­-controlled, parallel group, flexible dose study, to assess the effectiveness of controlled release ropinirole add-on therapy to L-dopa at increasing the time to onset of dyskinesia in Parkinson’s disease subjects”

“A 5-week, Randomized, Double-blind, Placebo-controlled Multi-center Study of [S, S]-Reboxetine in Patients with Postherpetic Neuralgia (PHN), who are Gabapentin Treatment Failures”

“A Multicenter, open-label trial to assess subject preference of PARCOPA, Carbidopa/Levodopa Orally disintegrating Tablets, compared to conventional Carbidopa/Levodopa Tablets in subjects with stable Parkinson’s Disease”

“A 4-Week Randomized, Multicenter, Double-blind, Placebo-and Active-controlled, Parallel-group. Forced-titration Phase llB Study Comparing Efficacy and Safety of Ascending Doses of xxxxx Prolonged Release Up To 233 mg BID and Oxycodone Prolonged release up to 20 mg BID to Placebo in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee”

 “A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study Assessing the Safety and Efficacy of XX XXXXX in Patients with Postherpetic Neuralgia”

“A Randomized, Parallel-Design, Multi-center Study to Evaluate the Efficacy of AVINZA ® for the Treatment of Chronic Low Back Pain”

“RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF) CO (XX IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE”

“A MULIT-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL TO ASSESS THE EFFICACY AND SAFETY OF XXX XXX (200, 400, AND 600MG/DAY) IN SUBJECTS WITH PAINFUL DISTAL DIABETIC NEUROPATHY”

“A randomized, double-blind, parallel group, placebo-controlled, single-attack evaluation of the efficacy and tolerability of Trexima (sumatriptan 85mg/ naproxen sodium SOOmgO tablets vs. placebo when administered during the mild pain phase of a migraine”

“A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SUBJECTIVE RESPONSE TO TREATMENT WITH RAMELTEON IN ADULT SUBJECTS WITH CHRONIC INSOMNIA BY UTILIZING AN INTERACTIVE VOICE RESPONSE SYSTEM (IVRS) FOR COLLECTING DIARY DATA”

“Phase 3 Multicenter, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment with XXX XXX on Measures of Cognitive and Global Function in Subjects with mild to Moderate Dementia of the Alzheimer’s Type”

“A prospective, multi-center, randomized, open-label study with blinded raters to evaluate the effects of immediate versus delayed switch to Stalevo® on motor function and quality of life in patients with Parkinson’s disease with end-of-dose wearing off”

“A randomized, multi-center, double-blind, placebo-controlled, 18-month study of the efficacy of Xaliproden in patients with mild-to-moderate dementia of the Alzheimer’s type”

“A MULIT-CENTER, RANDOMIZED, DOU BLE-BLIND, PLACEBO-CONTROLLED, FIVE-ARM PARALLEL-GROUP TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF FOUR DIFFERENT TRANSDERMAL DOSES OF ROTIGOTINE IN SUBJECTS WITH IDIOPATHIC RESTLESS LEGS SYNDOROME”

“AN OPEN-LABEL EXTENSION TRIAL TO INVESTIGATE THE SAFETY AND TOLERABILITY OF LONG-TERM TREAMENT WITH TRANSDERMAL ROTIGOTINE IN SUBJECTS WITH IDIPATHIC RESTLESS LEGS SYNDROME”

“A Pilot, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Nortriptyline HCI and Tramadol HCl in the Treatment of Chronic Lumbosacral Radiculopathy”

“A Randomized, Double-Blind, Placebo-Controlled Study of the safety and Efficacy of Gabapentin extended release (0-ER) Tablets in the Treatment of Patients with Postherpetic Neuralgia”

“An Open-label Exploratory Study with Memantine of Selected Measures of Volumetric MRI and Cognition in Patients with Moderate Dementia of the Alzheimer’s Type”

“SAFETY, TOLERABILITY, AND EFFICACY STUDY OF ORAL KETASYN (AC-1202) ADMINISTERED FOR NINETY DAYS IN SUBJECTS WITH PROBABLE ALZHEIMER’S DISEASE OF MILD TO MODERATE SERVERTIY”

“A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER PROOF-OF-CONCEPT STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ROZEREM”’ TAKEN IN COMBINATION WITH GABAPENTIN FOR THE TREATMENT OF SUBJECTS WITH CHRONIC INSOMNIA”

“A randomized, double-blind, multi-center, placebo-controlled, cross-over study to determine the consistency of response for Trexima (sumatriptan 85mg/naproxen sodium 500mg) administered during the mild pain phase for the acute treatment of multiple migraine attacks”

“A Randomized, Double-Blind, Placebo ­Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer Pain”

“A Randomized, Double-Blind, Placebo­ Controlled, Multicenter Phase 3 Study to Evaluate the Long-Term Safety of Alvimopan 0.5mg Twice Daily for 12 Months for the Treatment of  Opioid-­Induced Bowel Dysfunction in Adults taking Opiod Therapy for Persistent Non­Cancer Pain”

“A Multicenter Study Evaluating the Efficacy and Safety of Botox® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Headache Prohylaxis in Migraine Patients with 15 or More Headache Days per 4-Week Period in a 24-Week, Double Blind, Randomized, Placebo-Controlled, Parallel-                              Group Phase Followed by a 32-Week Open-Label Extension”

“A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of 8 Week Treatment of Rozerem 8 mg (OHS) in Sleep Disturbed, Community Dwelling, Mild to Moderately Sever Alzheimer’s Disease Subjects”

“A randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with new onset Parkinson’s disease”

“[S, S]-REBOXETINE DOSE-RANGE FINDING TRIAL: A 16-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO AND PREGABALIN CONTROLED, MULTI-CENTER TRIAL OF [S, S]-REBOXETINE IN PATINETS WITH POSTHERPETIC NEURALGIA (PHN.)”

“A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 2 Study Designed to Assess the Efficacy and Safety of X) (XXXX in Subjects with Painful Diabetic Neuropathy”

“A Randomized, Double-Blind, Active-Control, Parallel Group, 90-Day Safety Study of XX)(XXX Immediate Release or Oxycodone Immediate Release in Subjects With Chronic Pain From Low Back Pain or Osteoarthritis of the Hip or Knee”

“A Multicenter Trial Evaluating the Efficacy of CesamettM for the Symptomatic Treatment of Pain in Patients with Multiple Sclerosis”

“A Multicenter Trial Evaluating the Efficacy of Cesamet’^TM for the Symptomatic Treatment of Pain in Patients with Diabetic Peripheral Neuropathy”

“A Prospective, Multi-Center Clinical Evaluation of the Eon~ 16 Channel Implantable Pulse Generator (IPG) in combination with a lead tripole array for the management of chronic back pain with or without leg pain”

“A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy, Safety, and Tolerability of XXXXX in Levodopa Treated Parkinson’s Disease Patients with Motor Fluctuations”

“AN OPEN-LABEL EXTENSION TRIAL ASSESSING THE SAFETY AND TOLERABILITY OF [S, S]-REBOXETINE IN PATIENTS WITH POSTHERPETIC NEURALGIA (PHN)”